Molecular Imaging 2017

Treatment Response Assessment

Tumour Type Treatment

Imaging Findings

Author, Year

Symptomatic Myeloma:

Cyclophosphamide Lenalidomide , Bortezomib, Dexamethasone

DWI 50-900 T1, STIR

Increase in ADC with treatment SN: 86%, SP: 80%, PPV adj : 94.5%, NPV adj : 59%; prevalence of response: 80% Increase in ADC with treatment

Giles et al, 2014

Mixed population n=34 13 weeks

Symptomatic Myeloma n=12 3 weeks Symptomatic Myeloma n=20

Treatment not stated

DWI 50-800 T1, STIR

Horger et al, 2011

Cyclophosphamide Thalidomide Dexamethasone

DWI T1, STIR

Increase in ADC with treatment

Messiou et al 2012

4-6 weeks 20 weeks